MGUS (Monoclonal Gammopathy of Uncertain Significance) Service for Dorset

NHS Dorset considered the provider landscape and noted that, whilst other primary care providers may theoretically be capable of delivering elements of the service, Mid-Dorset PCN is the only provider currently operating the established Dorset MGUS monitoring model with existing processes, workforce, patient cohort knowledge and integration arrangements. No alternative provider was identified that would provide sufficient additional benefits to justify service transition for the duration of the proposed extension.NHS Dorset ICB is satisfied that Mid-Dorset PCN is the most suitable provider to continue delivery of the MGUS Monitoring Service. The provider has successfully delivered the service throughout the current MOU term, demonstrating quality, capability, integration with existing clinical pathways and value for money.

The service is fully operational, integrated with primary care and specialist haematology services, and there have been no identified performance, quality or governance concerns that would indicate the need to seek an alternative provider.

Having considered the provider landscape and available information, the ICB has not identified another provider capable of delivering materially improved outcomes, value or service benefits that would justify service transition during the proposed nine-month extension period.

Awarding this short-term extension mitigates operational and clinical continuity risks whilst allowing sufficient time for commissioners to complete a wider strategic review of the future commissioning model across the cluster footprint. NHS Dorset therefore considers Mid-Dorset PCN to be the most suitable provider in accordance with the Provider Selection Regime key criteria and basic selection criteria.